Tacrolimus is a class of immunosuppressants that in the treatment of idiopathic membranous nephropathy, a decrease in urinary protein can be seen after one month of administration, but it takes longer if cure is needed. Tacrolimus is mainly used for the prevention and treatment of graft rejection after liver or kidney transplantation. However, it has also been documented that the drug, in combination with low-dose glucocorticoid therapy, can be used to treat idiopathic membranous nephropathy. A decrease in 24-hour urine protein levels is seen when tested at 1 month of treatment, but it takes longer for significant improvement to occur. In case of serious infections, renal impairment, hepatic impairment, blood glucose abnormalities and other adverse reactions during treatment with the drug, it is recommended to dispose of them symptomatically or to stop using the drug. The use of the drug is prohibited in cases of hypersensitivity to the components of the drug and macrolides. Tacrolimus needs to be treated under the guidance of clinicians, the above time is only for reference, the specific use of drugs need to be clinicians according to the condition of comprehensive judgment.